जर्नल ऑफ ऑन्कोलॉजी मेडिसिन एंड प्रैक्टिस

There is a more progress has been made in the development of novel cancer treatments. But the cancer remained as a leading cause death in the world. The etiopathognesis of cancer is due to the because of genetic predisposition, and also there is some environmental factors associated with cancer are some of them are may be due to environmental toxins, and also life style and diet if the cancer is relapsed also there is a chances of high risk of death rates due to the toxicity of drugs. In current scenario the therapy for cancer is followed by Surgery Chemotherapy, radiotherapy, etc. through all this by current therapy we can’t cure cancer completely. The particularly chemotherapy is the most commonly used treatment to treat the cancer but this chemotherapy associated with more adverse effects which leads to severe. So the main purpose of brief review is to understand the current uses of crude drugs as an anticancer to have a better result of the drug targets in the cancer therapy as anticancer. But pharmacological role of these crude drugs in cancer therapy is not fully clear. But many researchers are in believed that these crude drugs are to have nutraceutical effects on cancer patients.

Objectives: The aim of this study is to evaluate the Covid-19 infection among pediatric oncology patients diagnosed in our centre in 15 months period starting January 2020, to assess their clinical characteristics, laboratory findings, treatment outcomes, and to address the department and hospital strategies for management of such cases during the pandemic. Our study included 29 subjects. Setting: It is a single centre study at King Fahad Specialist Hospital in Dammam which is 400 beds tertiary referral hospital with 27 beds pediatric oncology Ward, 4 beds bone marrow transplant and 18 bed pediatric oncology day care services. Methods and Results: We retrospectively reviewed all the patients with different types of pediatric malignancies diagnosed with Covid-19 infection from January 2020 to March 2021, from both inpatient and outpatient settings. Data about their type of malignancies, current treatment course, pattern of presentation, and the impact of their Covid -19 infection on their therapy while addressing on the same time the effects of their malignancy pattern and the therapy provided on the severity and morbidity of their Covid-19 infection. The study was approved by the ethics committee with IRB number: ONC0373-dated 14/12/2020. Conclusion: During the COVID-19 pandemic, children from different age groups caught COVID-19 infection without any significant age or gender preference; however, fortunately, the clinical manifestations of children’s COVID-19 disease were less severe than those of adult’s patients. In this study, despite the small number of cases and being single institute experience, we found that there is no significant impact of covid-19 infection on children with cancer under therapy in term of significant delays to their treatment, the clinical outcome or for increased complications or fatalities that known to be associated with Covid-19 infection.

The explosive growth of tele-health in oncology during the COVID-19 pandemic has been greeted by hematologists and oncologists with mixed emotions. While it allows for effective healthcare delivery while maintaining social distancing, it lacks the “personal touch” in a field where delivering life-altering news is common. We review the evolution of the medical healthcare models, focusing on the impact of tele-health during the COVID-19 crisis and discuss the long-term role of telemedicine in today’s service culture. We also discuss potential factors influencing the growth of telemedicine, including acceptability and familiarity with telehealth, development of associated infrastructure and business models supporting its growth.

Objectives: The aim of this study is to evaluate the clinical course, laboratory findings and treatment outcomes of the infant patients diagnosed with leukemia treated in our center.

Design: This is a retrospective study of all the patients below one year old who diagnosed with leukemia and treated in King Fahd specialist hospital in Dammam, pediatric hematology/ oncology department between 1st January 2011 and 1st December 2018, our study included 14 cases.

Setting: It is a single center study at King Fahad Specialist Hospital in Dammam which is 400 beds tertiary referral hospital with 27 beds pediatric oncology Ward, 2 beds bone marrow transplant and 18 bed pediatric oncology day care services.

Methods and Results: All data and information of patients including laboratory results were retrieved from patients’ files and electronic medical records. Data analysis was done by using Statistical Package for the Social Sciences (SPSS) program version.

Results: Within our study period we diagnosed 13 cases with infantile leukemia out of 202 cases of childhood leukemia in 8 years period (incidence of 6.4%) with overall survival of 61.5%.

Conclusion: The incidence of ALL in infants is significantly lower than in other groups of children it tends to be presented with aggressive clinical features at diagnosis, including hyper leukocytosis, massive organomegaly, and central nervous system (CNS) involvement. The management particularly challenging, the outcome is inferior with tendency towards refractory course and increased relapse rates. In our study the survival rate was 61.5% which is minor better than what was reported in some centers for theses group of patients probably masked by the small number of patients in our study. More studies with larger patient numbers are needed to reevaluate HSCT's eligibility criteria in this group of patients, in addition to studying some new strategies such as CAR-T cell, targeted therapies, improving conditioning regimens, and maximize the supportive care should all be considered to improve the prognosis.